← All trials
NCT05132920
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Nov 30, 2024
- Completion date
- Nov 30, 2025
- First posted
- Nov 24, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 334
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BonnLead sponsor
- University of BonnReponsible party - principal investigator
- German Federal Ministry of Education and ResearchCollaborator
- Friedrich Wilhelms UniversityOverall official - principal investigator
- nextevidence GmbHCollaborator
- University of LeipzigCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.